» Articles » PMID: 16371046

Hyperhemolysis Syndrome in Anemia of Chronic Disease

Overview
Journal Transfusion
Specialty Hematology
Date 2005 Dec 24
PMID 16371046
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Occasional cases of delayed hemolytic transfusion reaction (DHTR) demonstrate severe and persistent hemolysis and are referred to as hyperhemolysis syndrome. This syndrome usually occurs in patients with sickle cell disease and possibly thalassemia who receive multiple transfusions. There are few such clinical reports in patients without hemoglobinopathies.

Case Report: A 67-year-old woman with anemia and a history of four previous transfusions was admitted with shortness of breath and a hematocrit (Hct) level of 27 percent. The patient was group O with a negative antibody screen. She received 1 unit of electronically cross-matched red blood cells (RBCs) and was discharged. Thirteen days later she returned to hospital with weakness and a Hct level of 23 percent. The antibody screen now demonstrated anti-K alloantibody. The direct antigloblulin test (DAT) was positive with both anti-immunoglobulin G and anti-complement (C3). Anti-K was recovered in the eluate. The previously transfused RBC unit was positive for presence of the K antigen. The patient's RBCs were negative for the presence of K antigen. Other laboratory data confirmed ongoing hemolysis, and a diagnosis of DHTR was made. She continued to display findings of active hemolysis for 9 more weeks requiring 19 units of RBCs. Thirty-four days after the original transfusion, her DAT remained positive and both the plasma sample and a RBC eluate demonstrated anti-K.

Conclusion: The delayed hemolytic transfusion reaction with hyperhemolysis can occur among patients without hemoglobinopathies.

Citing Articles

Adverse events of red blood cell transfusions in patients with sickle cell disease.

Rollins M, Chou S Transfus Apher Sci. 2022; 61(5):103557.

PMID: 36064527 PMC: 10149091. DOI: 10.1016/j.transci.2022.103557.


Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature.

Menakuru S, Priscu A, Dhillon V, Salih A Hematol Rep. 2022; 14(3):235-239.

PMID: 35893156 PMC: 9326715. DOI: 10.3390/hematolrep14030032.


Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration.

Cannas G, Dubreuil L, Fichez A, Gerfaud-Valentin M, Debard A, Hot A Am J Case Rep. 2021; 22:e931107.

PMID: 33983909 PMC: 8130975. DOI: 10.12659/AJCR.931107.


Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease and the Role of the Classical Complement Pathway: A Case Report.

Hair P, Heck T, Carr D, Watson K, Price J, Krishna N J Hematol. 2021; 10(1):18-21.

PMID: 33643505 PMC: 7891913. DOI: 10.14740/jh553.


Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.

Madu A, Ugwu A, Efobi C Med Princ Pract. 2020; 30(3):236-243.

PMID: 33176303 PMC: 8280419. DOI: 10.1159/000512945.